Trial Profile

A Phase Ⅰb Study Evaluating the Pharmacokinetic,Safety and Efficacy of Remimazolam Tosylate in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Remimazolam (Primary)
Indications Anaesthesia; Insomnia; Sedation
Focus Pharmacokinetics
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

13 Mar 2020 Results (n=87; Chinese volunteers) of two clinical studies: NCT01970072: Midazolam based and NCT03444480 Flumazenil based assessing residual psychomotor effects of remimazolam and their recovery from sedating treatment in 2 simulated clinical settings: single dose administration for sedation initiation and constant rate infusion for sedation maintenance were published in the Clinical Therapeutics
26 Feb 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com